Takara Bio to Acquire Clontech Unit of BD Biosciences
Takara Bio Inc. announced that it has entered into a definitive agreement to acquire the Clontech unit ("Clontech") of BD Biosciences, mainly consisting of Clontech Laboratories Inc. (employees: 190), for USD $60 million (adjusted from USD $65 million due to the retention of certain inventories and receivables by the seller), from BD. The acquisition, which is subject to regulatory approvals, is expected to close by August 2005 and will be made through a wholly-owned subsidiary of Takara Bio to be established in the US.
Clontech Laboratories Inc. (Palo Alto, CA), founded in 1984, was acquired by BD in 1999. Clontech develops, manufactures and markets innovative biological products to the life science market worldwide and has established a strong position especially in the molecular biology research area. Clontech's products are widely used in the area of gene identification, gene expression, and gene functional analysis. For fiscal year 2004, Clontech reported total revenues of around USD $60 million worldwide.
Since starting to manufacture and supply restriction enzymes in 1979, Takara Bio has positioned itself as a leading company in the Japanese life science market and first introduced PCR related products in Japan. The company's revenues in the research reagent business worldwide were ¥11.8 billion JPY for fiscal 2004.
Takara Bio Europe announced that it will start selling its range of Takara brand products exclusively and directly to customers in the UK, Germany, Austria and Switzerland, with immediate effect. The decision means customers will be able to buy both Takara and Clontech brand products from o ... more
MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc..
Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation ... more
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains r ... more
Takara Bio Europe and Clontech Laboratories are members of the Takara Bio Group, a leading supplier of tools for life scientists worldwide.
Through our brand names Takara® and Clontech® we develop innovative technologies in the fields of Cell Biology, Molecular Biology and Proteomics.
Tak ... more
BD (Becton, Dickinson and Company) announced the release of a study by researchers from the Johns Hopkins Bloomberg School of Public Health at the XVI International AIDS Conference (AIDS 2006) that demonstrated conducting CD4 tests is a cost-effective laboratory testing strategy for managin ... more
BD Biosciences, a segment of BD, announced a licensing and research agreement with Dynomics BV in the fields of leukemia and lymphoma. Under terms of the agreement, BD has an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion prot ... more
BD (Becton, Dickinson and Company) announced the completion of its acquisition of GeneOhm Sciences, Inc., a pioneer in the development of molecular diagnostic testing for the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs), a gr ... more
Right from the start, BD SENSORS has specialized in electronic pressure and level measurement. Apart from an extensive product program BD SENSORS almost offers for each application a suitable solution more
BD Biosciences is one of three business segments of BD (Becton, Dickinson and Company) built on BD's 100-year foundation of quality, reliability, and commitment to customers and business partners around the world. As one of the largest businesses supporting the life sciences today, BD Biosc ... more